On May 8, 2019, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced first quarter 2019 financial results.  The company announced that it had entered into an agreement to acquire ATI-502, a topical treatment for the treatment of alopecia areata.  The agreement is subject to approval by the U.S. District Court for the District of Columbia.  The agreement is subject to court approval by the court.  The agreement is subject to court approval.  According to the SEC's order, ATI-502 is a topical treatment that targets the production activity of TNF alpha, IL-1, IL-6 and IL-8.  ATI-502 is a topical treatment for the treatment of hair loss.  The agreement requires ATI-502 to be approved by the U.S. Department of Health and Human Services.  The agreement also requires ATI-502 to be approved by the FDA.  The settlement is subject to court approval.  The settlement is subject to court approval by the Court.  The SEC's investigation, which is continuing, has been conducted in the SEC's Philadelphia Regional Office.  The litigation will be led by Neal Walker.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Columbia, the Federal Bureau of Investigation, and the Internal Revenue Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.govÂ Investor.govÂ to quickly identify whether they are registered professionals.  The SEC's Office of Investor Education has also issued an Investor Alert about ATI-502.  The SEC encourages investors to check the backgrounds of people selling or offering them an investment usingÂ Investor.govÂ to identify whether they are registered professionals.